Tarsus Pharmaceuticals, Inc.
TARSNASDAQHealthcare● Active
$60.82
+$1.18(+1.98%)
Market Cap$2.6B
P/E Ratio—
52W High$85.25
52W Low$38.51
Tarsus Pharmaceuticals, Inc. (TARS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TARS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.07B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.04B | $0.03B | $0.02B | $0.01B | $0.01B |
| Change in Working Capital | $0.01B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Net Cash from Operations | ($0.01B) | ($0.08B) | ($0.12B) | ($0.05B) | $0.00B |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.00B) | ($0.01B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.39B) | ($0.27B) | ($0.03B) | ($0.15B) | $0.00B |
| Sales of Investments | $0.36B | $0.07B | $0.17B | $0.01B | $0.00B |
| Net Cash from Investing | ($0.04B) | ($0.20B) | $0.14B | ($0.14B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.04B | $0.01B | $0.02B | $0.00B |
| Net Cash from Financing | $0.14B | $0.15B | $0.13B | $0.09B | $0.00B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.02B) | ($0.08B) | ($0.12B) | ($0.05B) | $0.00B |
| FCF Margin %(computed) | -4.94% | -46.24% | -704.96% | -191.88% | 5.54% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Tarsus Pharmaceuticals, Inc. data
About Tarsus Pharmaceuticals, Inc. (TARS) Cash Flow Statement
Tarsus Pharmaceuticals, Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.02B) for 2025 — a FCF margin of -4.94%. Capital expenditure was ($0.01B).
Frequently asked questions
TARS · 4 questionsTarsus Pharmaceuticals, Inc. generated free cash flow of ($0.02B) for 2025, up 73.6% year-over-year.
TARS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10